Robert Schlegl
27Patents
6h-index
32Co-inventors
69Inventor score
Filing activity: Oct 2, 2002 → Jun 14, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8765148B2 | 1C31 nanoparticles | Emerging Cross-Sectional Technologies | 17 | Active |
| US10537630B2 | Virus purification | Emerging Cross-Sectional Technologies | 13 | Active |
| US7651848B2 | Method for refolding a protein | Chemistry; Metallurgy | 10 | Active |
| US10744194B2 | Zika virus purification | Emerging Cross-Sectional Technologies | 9 | Active |
| US11219681B2 | Zika virus vaccine | Emerging Cross-Sectional Technologies | 8 | Active |
| US10544194B2 | Mutant fragments of OspA and methods and uses relating thereto | Emerging Cross-Sectional Technologies | 7 | Active |
| US10639365B2 | Zika virus vaccine | Emerging Cross-Sectional Technologies | 6 | Active |
| US10660950B2 | Virus purification | Emerging Cross-Sectional Technologies | 6 | Active |
| US11331382B2 | Zika virus purification | Emerging Cross-Sectional Technologies | 4 | Active |
| US11466058B2 | Mutant fragments of OspA and methods and uses relating thereto | Emerging Cross-Sectional Technologies | 3 | Active |
| US11484587B2 | Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3 | Emerging Cross-Sectional Technologies | 2 | Active |
| US10662412B2 | Aseptic purification process for viruses | Chemistry; Metallurgy | 1 | Active |
| US11684669B2 | CpG-adjuvanted SARS-CoV-2 virus vaccine | Emerging Cross-Sectional Technologies | 1 | Active |
| US9913898B2 | Aluminum compounds for use in therapeutics and vaccines | Emerging Cross-Sectional Technologies | 1 | Active |
| US9884115B2 | Aluminum compounds for use in therapeutics and vaccines | Emerging Cross-Sectional Technologies | 1 | Active |
| US10668146B2 | Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines | Emerging Cross-Sectional Technologies | 1 | Active |
| US9895437B2 | Aluminum compounds for use in therapeutics and vaccines | Emerging Cross-Sectional Technologies | 1 | Active |
| US7060460B2 | Method for reconstituting a recombinant protein to its biologically active form | Chemistry; Metallurgy | 1 | Expired |
| US12102673B2 | Zika virus vaccine | Emerging Cross-Sectional Technologies | 0 | Active |
| US11110170B2 | Aluminum compounds for use in therapeutics and vaccines | Emerging Cross-Sectional Technologies | 0 | Active |
| US9248180B2 | IC31 nanoparticles | Emerging Cross-Sectional Technologies | 0 | Active |
| US9359412B2 | OprF/I fusion proteins, their preparation and use | Chemistry; Metallurgy | 0 | Active |
| US11951163B2 | Zika virus vaccine | Emerging Cross-Sectional Technologies | 0 | Active |
| US12011477B2 | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3 | Emerging Cross-Sectional Technologies | 0 | Active |
| US12214033B2 | Virus purification | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.